StockNews.AI
HROW
StockNews.AI
155 days

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

1. Harrow delays audited financial results due to auditor's request for more time. 2. Preliminary results and revenue guidance for 2025 were announced.

+15.69%Current Return
VS
-1.06%S&P 500
$23.3203/17 04:15 PM EDTEvent Start

$26.9803/18 10:52 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bearish?

Delays in financial reporting can lead to investor uncertainty and price drops. Historical instances show that companies experiencing delays often see immediate declines in stock prices.

How important is it?

The article discusses critical earnings data, impacting investor confidence and market perceptions. The potential risk of financial irregularities might concern stakeholders.

Why Short Term?

Investor sentiment may quickly react to the delay, impacting stock price temporarily. Past similar cases indicate that adjustments usually occur within a few weeks post-announcement.

Related Companies

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company's new independent auditor requires additional time to audit Harrow's financial presentation. As a result, Harrow is delaying its earn.

Related News